Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

News: Breast Cancer

VU study to explore Accountable Care Organizations’ impact on cancer screenings

Friday, May 29th, 2015

As health care organizations implement new strategies to improve quality and reduce costs, a physician researcher at VUMC is setting out to identify whether there could be unintended effects. Matthew Resnick, M.D., MPH, assistant professor of Urologic Surgery and Health Policy, has been awarded a $726,000 grant from the American Cancer Society to study the […]

Jansen’s cancer research efforts garner recognition

Thursday, May 14th, 2015

Valerie Malyvanh Jansen, M.D., Ph.D., a third-year medical oncology fellow, recently received several national awards and grants, as well as a Vanderbilt-Ingram Cancer Center fellowship, in recognition of her translational cancer research. Jansen received an American Association for Cancer Research (AACR) 2015 Women in Cancer Research Scholars Award. The awards are given to members of […]

VICC research efforts in spotlight at AACR conference

Thursday, April 30th, 2015

Adding an investigational drug to an already approved estrogen blocking therapy appears to be safe and provided clinical benefit for some postmenopausal women with estrogen-positive breast cancer. The research led by Ingrid Mayer, M.D., associate professor of Medicine and clinical director of the Breast Cancer Program at Vanderbilt-Ingram Cancer Center (VICC), was selected for the […]

Cancer signaling pathway blocker

Friday, April 10th, 2015

Researchers at Vanderbilt University have discovered a new way to inhibit Hedgehog (Hh) signaling, an important regulatory pathway for vertebrate development – and cancer. Abnormal regulation of this pathway leads to several human malignancies, including small cell lung cancer and pancreatic cancer, and therefore it is a potential drug target for cancer. Small molecules have […]

Micelle “packets” deliver cancer drugs

Friday, April 10th, 2015

Small interfering RNA (siRNA) molecules can suppress tumor growth and target cells otherwise untreatable by conventional therapeutics, but targeted, intracellular delivery is a significant limitation to siRNA translation. To deliver the siRNA molecules into tumor cells, researchers have packaged them in micelles that express folic acid, which is internalized by cancer cells that overexpress folate […]

NCI report shows U.S. cancer deaths on decline

Thursday, April 2nd, 2015

The death rates for most forms of cancer continue to decline at a modest pace among men, women and children in the United States, according to the Annual Report to the Nation on the Status of Cancer 1975 – 2011. The report from the National Cancer Institute, a division of the National Institutes of Health, […]

Arteaga named a fellow of the AACR Academy

Thursday, February 26th, 2015

Carlos L. Arteaga, M.D., director of the Center for Cancer Targeted Therapies and director of the Breast Cancer Program at Vanderbilt-Ingram Cancer Center (VICC), has been named a fellow of the AACR Academy. He is among 11 new fellows announced by the American Association for Cancer Research, the largest international cancer organization dedicated to cancer […]

Pink Out! game set for Sunday, Feb. 8

Thursday, February 5th, 2015

The stands inside Memorial Gymnasium are expected to resemble a sea of pink as fans don pink attire for the Vanderbilt Commodores Women’s Basketball game Sunday, Feb. 8, at noon. The Commodores will play the University of Kentucky Wildcats during the annual Pink Out! Game, which is designed to raise awareness of breast cancer and […]

Enzyme affects tumor metastasis

Thursday, January 8th, 2015

Breast cancer remains the most common type of cancer in females, with survival rates decreasing sharply for those with distant metastases. MMP2, a type of enzyme that degrades the extracellular matrix, has previously been implicated in the development of distant tumor metastases, but without a clearly defined role. In the Journal of Pathology, Barbara Fingleton, […]

Combo therapy may help fight melanoma

Thursday, January 8th, 2015

Two therapies already in clinical development as single agents may work in combination to treat many subtypes of melanoma, a recent study suggests.

Next Page »